Vor Biopharma (NASDAQ:VOR) Shares Down 4.4% – Should You Sell?

Shares of Vor Biopharma Inc. (NASDAQ:VOR) fell 4.4% during mid-day trading on Monday . The stock traded as low as $15.49 and last traded at $15.8650. 193,144 shares changed hands during trading, a decline of 81% from the average session volume of 1,019,325 shares. The stock had previously closed at $16.59.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on VOR. Citigroup began coverage on Vor Biopharma in a report on Friday, January 9th. They set a “buy” rating and a $50.00 price objective for the company. Jefferies Financial Group began coverage on Vor Biopharma in a report on Monday, March 30th. They set a “buy” rating and a $50.00 price objective for the company. Wedbush lifted their price objective on Vor Biopharma to $15.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. HC Wainwright reduced their price objective on Vor Biopharma from $32.00 to $31.00 and set a “buy” rating for the company in a report on Wednesday, April 15th. Finally, Wells Fargo & Company began coverage on Vor Biopharma in a report on Thursday, March 19th. They set an “overweight” rating and a $30.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Vor Biopharma has an average rating of “Moderate Buy” and a consensus target price of $50.56.

Vor Biopharma Price Performance

The firm has a market cap of $741.05 million, a PE ratio of -0.04 and a beta of 1.92. The stock has a 50-day moving average price of $14.80 and a 200 day moving average price of $15.82.

Insider Activity at Vor Biopharma

In other news, Director Ra Capital Management, L.P. sold 171,963 shares of Vor Biopharma stock in a transaction on Monday, April 20th. The stock was sold at an average price of $15.77, for a total value of $2,711,856.51. Following the completion of the sale, the director owned 2,567,245 shares of the company’s stock, valued at $40,485,453.65. The trade was a 6.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 2,837,753 shares of company stock valued at $46,807,761 over the last ninety days. 0.45% of the stock is owned by insiders.

Institutional Investors Weigh In On Vor Biopharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. RA Capital Management L.P. grew its position in shares of Vor Biopharma by 172.7% in the fourth quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock valued at $70,697,000 after purchasing an additional 3,422,697 shares during the period. Fcpm Iii Services B.V. grew its position in shares of Vor Biopharma by 852.8% in the fourth quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company’s stock valued at $47,315,000 after purchasing an additional 3,237,714 shares during the period. Frazier Life Sciences Management L.P. purchased a new stake in shares of Vor Biopharma in the fourth quarter valued at $33,275,000. Paradigm Biocapital Advisors LP purchased a new stake in shares of Vor Biopharma in the fourth quarter valued at $22,890,000. Finally, NEXTBio Capital Management LP purchased a new stake in shares of Vor Biopharma in the fourth quarter valued at $13,080,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).